Biocryst Pharmaceuticals Share Price (NASDAQ: BCRX)

$8.34

▲

0.06

(0.72%)

Live

Last updated on August 20, 2025 at 11:37 PM IST

$₹

Check the interactive Biocryst Pharmaceuticals Stock chart to analyse performance

Biocryst Pharmaceuticals stock performance

as on August 20, 2025 at 11:37 PM IST

Today's Low:$8.24
Today's High:$8.34
$8.34
1.2%
Downside
Day's Volatility :1.2%
Upside
0.0%
52 Weeks Low:$6.02
52 Weeks High:$11.31
$8.34
27.88%
Downside
52 Weeks Volatility :46.82%
Upside
26.26%

Biocryst Pharmaceuticals Stock Returns

Period	Biocryst Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-17.83%	1.5%	0.0%
6 Months	-11.87%	-7.1%	0.0%
1 Year	5.82%	-11.4%	0.0%
3 Years	-40.81%	2.9%	-9.6%

Biocryst Pharmaceuticals Inc Key Stats

Check Biocryst Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$8.28
Open	$8.35
Today's High	$8.34
Today's Low	$8.24
Market Capitalization	$1.8B
Today's Volume	$2.3M
52 Week High	$11.31
52 Week Low	$6.015
Revenue TTM	$557.5M
EBITDA	$58.5M
Earnings Per Share (EPS)	$-0.18
Profit Margin	-6.41%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1925.37%

Stock Returns calculator for Biocryst Pharmaceuticals Stock including INR - Dollar returns

The Biocryst Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Biocryst Pharmaceuticals investment value today

Current value as on today

₹1,10,538

Returns

₹10,538

(+10.54%)

Returns from Biocryst Pharmaceuticals Stock

₹6,650 (+6.65%)

Dollar Returns*

₹3,889 (+3.89%)

Indian investors sentiment towards Biocryst Pharmaceuticals Stock

100%

Period: Jul 20, 2025 to Aug 19, 2025. Change in 30 Days versus previous period

Search interest for Biocryst Pharmaceuticals Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Biocryst Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
10.85%
Vanguard Group Inc
9.79%
Kynam Capital Management, LP
4.03%
State Street Corp
3.72%
Alkeon Capital Management, LLC
2.72%
Deerfield Management Co
2.47%

Analyst Recommendation on Biocryst Pharmaceuticals Stock

Rating

Trend

Buy

83%Buy

16%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Biocryst Pharmaceuticals(by analysts ranked 0 to 5 stars)

Biocryst Pharmaceuticals Share Price Target

What analysts predicted

Upside of 100.57%

Target:

$16.73

Current:

$8.34

Biocryst Pharmaceuticals share price target is $16.73, a slight Upside of 100.57% compared to current price of $8.34 as per analysts' prediction.

Biocryst Pharmaceuticals Stock Insights

Price Movement
In the last 3 months, BCRX stock has moved down by -19.9%
Increasing Revenue
Revenue is up for the last 6 quarters, 92.76M → 163.35M (in $), with an average increase of 10.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -26.79M → 5.08M (in $), with an average increase of 41966.9% per quarter
BCRX vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 63.0% return, outperforming this stock by 104.4%

Biocryst Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$48.8M	↑ 136.45%
Net Income	$-120.1M	↑ 18.58%
Net Profit Margin	-245.86%	↑ 244.39%

	FY20	Y/Y Change
Revenue	$17.8M	↓ 63.53%
Net Income	$-182.8M	↑ 52.26%
Net Profit Margin	-1.0K%	↓ 780.49%

	FY21	Y/Y Change
Revenue	$157.2M	↑ 782.38%
Net Income	$-184.1M	↑ 0.68%
Net Profit Margin	-117.11%	↑ 909.24%

	FY22	Y/Y Change
Revenue	$270.8M	↑ 72.31%
Net Income	$-247.1M	↑ 34.26%
Net Profit Margin	-91.24%	↑ 25.87%

	FY23	Y/Y Change
Revenue	$331.4M	↑ 22.37%
Net Income	$-226.5M	↓ 8.33%
Net Profit Margin	-68.36%	↑ 22.88%

	FY24	Y/Y Change
Revenue	$450.7M	↑ 36.0%
Net Income	$-88.9M	↓ 60.77%
Net Profit Margin	-19.72%	↑ 48.64%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$92.8M	↓ 0.69%
Net Income	$-35.4M	↓ 42.69%
Net Profit Margin	-38.14%	↑ 27.95%

	Q2 FY24	Q/Q Change
Revenue	$109.3M	↑ 17.86%
Net Income	$-12.7M	↓ 64.18%
Net Profit Margin	-11.59%	↑ 26.55%

	Q3 FY24	Q/Q Change
Revenue	$117.1M	↑ 7.09%
Net Income	$-14.0M	↑ 10.72%
Net Profit Margin	-11.99%	↓ 0.4%

	Q4 FY24	Q/Q Change
Revenue	$131.5M	↑ 12.34%
Net Income	$-26.8M	↑ 90.94%
Net Profit Margin	-20.37%	↓ 8.38%

	Q1 FY25	Q/Q Change
Revenue	$145.5M	↑ 10.64%
Net Income	$32.0K	↓ 100.12%
Net Profit Margin	0.02%	↑ 20.39%

	Q2 FY25	Q/Q Change
Revenue	$163.4M	↑ 12.24%
Net Income	$5.1M	↑ 15790.63%
Net Profit Margin	3.11%	↑ 3.09%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$44.7M	↑ 121.65%

	FY20	Y/Y Change
Profit	$16.1M	↓ 63.93%

	FY21	Y/Y Change
Profit	$149.1M	↑ 824.2%

	FY22	Y/Y Change
Profit	$262.8M	↑ 76.22%

	FY23	Y/Y Change
Profit	$325.1M	↑ 23.71%

	FY24	Y/Y Change
Profit	$438.4M	↑ 34.87%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$91.5M	↑ 0.17%

	Q2 FY24	Q/Q Change
Profit	$107.6M	↑ 17.6%

	Q3 FY24	Q/Q Change
Profit	$113.9M	↑ 5.82%

	Q4 FY24	Q/Q Change
Profit	$125.4M	↑ 10.14%

	Q1 FY25	Q/Q Change
Profit	$141.0M	↑ 12.41%

	Q2 FY25	Q/Q Change
Profit	$160.6M	↑ 13.9%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-89.6M	↓ 3.22%
Investing Cash Flow	$77.9M	↑ 1534.52%
Financing Cash Flow	$99.1M	↑ 58.55%

	FY20	Y/Y Change
Operating Cash Flow	$-135.1M	↑ 50.82%
Investing Cash Flow	$-6.9M	↓ 108.8%
Financing Cash Flow	$300.6M	↑ 203.32%

	FY21	Y/Y Change
Operating Cash Flow	$-142.2M	↑ 5.22%
Investing Cash Flow	$15.8M	↓ 330.51%
Financing Cash Flow	$359.7M	↑ 19.65%

	FY22	Y/Y Change
Operating Cash Flow	$-161.9M	↑ 13.85%
Investing Cash Flow	$-128.2M	↓ 911.43%
Financing Cash Flow	$88.0M	↓ 75.53%

	FY23	Y/Y Change
Operating Cash Flow	$-95.1M	↓ 41.22%
Investing Cash Flow	$-131.5M	↑ 2.54%
Financing Cash Flow	$32.5M	↓ 63.1%

	FY24	Y/Y Change
Operating Cash Flow	$-52.0M	↓ 45.32%
Investing Cash Flow	$52.6M	↓ 140.0%
Financing Cash Flow	$-5.8M	↓ 117.73%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-53.7M	↑ 501.97%
Investing Cash Flow	$28.8M	↓ 200.99%
Financing Cash Flow	$-1.0M	↓ 66.97%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-1.4M	↓ 97.45%
Investing Cash Flow	$-2.4M	↓ 108.52%
Financing Cash Flow	$-2.0M	↑ 87.6%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$8.2M	↓ 702.7%
Investing Cash Flow	$8.5M	↓ 446.63%
Financing Cash Flow	$1.3M	↓ 164.8%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-5.2M	↓ 163.23%
Investing Cash Flow	$17.8M	↑ 109.65%
Financing Cash Flow	$-4.0M	↓ 415.62%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-27.5M	↑ 427.85%
Investing Cash Flow	$27.1M	↑ 52.24%
Financing Cash Flow	$529.0K	↓ 113.16%

Biocryst Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Biocryst Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Biocryst Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biocryst Pharmaceuticals Inc	-2.88%	-11.87%	5.82%	-40.81%	98.68%
Haleon Plc Spon Ads	2.31%	-2.3%	-1.02%	56.75%	31.58%
United Therapeutics Corporation	6.99%	-17.64%	-9.59%	42.35%	76.36%
Zoetis Inc.	5.63%	-0.62%	-15.21%	-5.68%	-1.7%
Neurocrine Biosciences Inc.	0.78%	16.28%	-11.18%	25.09%	17.46%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biocryst Pharmaceuticals Inc	NA	NA	-0.28	0.15	-19.25	0.07	NA	-2.01
Haleon Plc Spon Ads	21.51	21.51	3.09	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	12.22	12.22	1.43	26.61	0.19	0.13	NA	158.65
Zoetis Inc.	26.84	26.84	2.47	6.32	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	39.29	39.29	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biocryst Pharmaceuticals Inc	Buy	$1.8B	98.68%	NA	-6.41%
Haleon Plc Spon Ads	Buy	$43.4B	31.58%	21.51	13.81%
United Therapeutics Corporation	Buy	$14.2B	76.36%	12.22	40.36%
Zoetis Inc.	Buy	$69.0B	-1.7%	26.84	27.83%
Neurocrine Biosciences Inc.	Buy	$13.2B	17.46%	39.29	13.88%

About Biocryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Organization	Biocryst Pharmaceuticals
Employees	580
CEO	Mr. Jon P. Stonehouse
Industry	Health Technology

Key Management of Biocryst Pharmaceuticals Inc

Name	Title
Mr. Jon P. Stonehouse	CEO & Executive Director
Mr. Charles K. Gayer	President
Ms. Alane P. Barnes	Senior VP, Chief Legal Officer & Corporate Secretary
Dr. Helen M. Thackray FAAP, M.D.	Chief Research & Development Officer
Mr. Babar Ghias	CFO & Head of Corporate Development

Important FAQs about investing in BCRX Stock from India :

What is Biocryst Pharmaceuticals share price today?

Biocryst Pharmaceuticals share price today is $8.34 as on August 20, 2025 at 11:37 PM IST. Biocryst Pharmaceuticals share today touched a day high of $8.34 and a low of $8.24.

What is the 52 week high and 52 week low for Biocryst Pharmaceuticals share?

Biocryst Pharmaceuticals share touched a 52 week high of $11.31 and a 52 week low of $6.02. Biocryst Pharmaceuticals stock price today i.e. August 20, 2025 at 11:37 PM IST is trending at $8.34, lower by 26.26% versus the 52 week high.

How to invest in Biocryst Pharmaceuticals Stock (BCRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Biocryst Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Biocryst Pharmaceuticals Shares that will get you 0.1799 shares as per Biocryst Pharmaceuticals share price of $8.34 per share as on August 20, 2025 at 11:37 PM IST.

What is the minimum amount required to buy Biocryst Pharmaceuticals Stock (BCRX) from India?

Indian investors can start investing in Biocryst Pharmaceuticals (BCRX) shares with as little as ₹87.0225 or $1 (as of August 20, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹870.22 in Biocryst Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 20, 2025). Based on Biocryst Pharmaceuticals share’s latest price of $8.34 as on August 20, 2025 at 11:37 PM IST, you will get 1.1990 shares of Biocryst Pharmaceuticals. Learn more about fractional shares .

What are the returns that Biocryst Pharmaceuticals has given to Indian investors in the last 5 years?

Biocryst Pharmaceuticals stock has given 98.68% share price returns and 16.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?